MSMaarten L. Simoons

Maarten L. Simoons

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maarten L. Simoons has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 18 September 2004
      • Vol. 148  (38) , 1878-82

    [Treatment of patients with acute coronary syndromes in the Netherlands in 2000-2001; a comparison with other European countries and with the guidelines].

    by R Nieuwlaat, F Vermeer, W J M Scholte Op Reimer, E Boersma, A W J Van 't Hof, M L Simoons

    To determine whether the guidelines for the management of acute coronary syndrome (ACS) are being applied in daily clinical practice, and in what ways the management differs between the Netherlands and other member countries of the European Society of Cardiology (ESC). Prospective, observational study. Patients with a confirmed diagnosis of ACS who were enrolled in 6 Dutch hospitals and in 97 hospitals in 24 other ESC member countries in the period from 4 September 2000 to 15 May 2001 were included. Data were collected on the acute treatment and secondary prevention in patients with ST-elevation and on the pharmacotherapy, risk stratification and secondary prevention in patients without ST-elevation. The findings were compared with the recommendations and guidelines of the ESC. A total of 223 patients with ST-elevation and 198 patients without ST-elevation were enrolled in the Netherlands, plus 4208 and 5169 patients, respectively, in the other European countries. The median age was 64-67 years and the percentage of males was 64-73. Of the patients with ST-elevation who arrived in the hospital within 12 hours after the onset of symptoms, 35% received neither thrombolysis nor primary percutaneus coronary intervention. In both the Netherlands and the rest of Europe, half of the ST-elevation patients received thrombolysis later than 40 minutes and primary percutaneous coronary intervention later than 90 minutes after arrival in the hospital. Risk stratification using troponin measurements was applied more often in the Netherlands. Of the high-risk patients without ST-elevation, over 50% in both the Netherlands and the rest of Europe underwent coronary angiography. Almost 70% and 80% of low-risk, non-ST-elevation patients underwent an exercise tolerance test or coronary angiography. In the Netherlands, clopidogrel, glycoprotein IIb/IIIa antagonists and statins were prescribed more often and ACE inhibitors less often. Guidelines for the management of ACS were followed to a moderate extent in both the Netherlands and the rest of Europe. The management differed in a number of ways between the Netherlands and the other countries.


  • Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IV–ACS

    by Timo Lenderink, Eric Boersma, Witold Ruzyllo, Petr Widimsky, E Magnus Ohman, Paul W Armstrong, Lars Wallentin, Maarten L Simoons, GUSTO IV-ACS Investigators


  • Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina

    by J.P. Ottervanger, P. Armstrong, E.S. Barnathan, E. Boersma, J.S. Cooper, E.M. Ohman, S. James, E. Topol, L. Wallentin, M.L. Simoons

    Background— This study was designed to investigate long-term effects of the glycoprotein IIb/IIIa inhibitor abciximab in patients with acute coronary syndrome without ST elevation who were not scheduled for coronary intervention. Methods and Results— A total of 7800 patients were included with an acute coronary syndrome without ST elevation, documented by either elevated cardiac troponin or transient or persistent ST-segment depression. They were randomized to abciximab bolus and 24-hour infusion, abciximab bolus and 48-hour infusion, or matching placebo. The overall 1-year mortality rate was 8.3% (649 patients). One-year mortality was 7.8% in the placebo group and 8.2% in the 24-hour and 9.0% in the 48-hour abciximab infusion group. Compared with placebo, the hazard ratio for the 24-hour infusion of abciximab was 1.1 (95% CI 0.86 to 1.29), and for the 48-hour infusion, it was 1.2 (95% CI 0.95 to 1.41). The lack of benefit of abciximab was observed in every subgroup studied. Patients with negative troponin or elevated C-reactive protein had a higher mortality rate after treatment with abciximab for 48 hours than with placebo: 8.5% versus 5.8% in those with negative troponin ( P =0.02), 16.3% versus 12.1% in those with elevated C-reactive protein ( P =0.04). Conclusions— Compared with placebo, abciximab did not provide any survival benefit at 1 year in patients admitted with an acute coronary syndrome with ST depression and/or elevated troponin who were not scheduled to undergo early coronary revascularization. In subgroups of patients, in particular those with low cardiac troponin or elevated C-reactive protein, abciximab was associated with excess mortality.


  • Open Access

    Cardio-vascular disease in Europe: challenges for the medical profession Opening address of the 2002 Congress European Society of Cardiology

    by Maarten L Simoons

    The European Union has adopted the HeartPlan for Europe, which has been presented by the European Society of Cardiology to the SpanishMinister of Health.


    • 20 October 2001
      • Vol. 145  (42) , 2029-35

    [Twelve year triage and thrombolysis treatment prior to hospitalization for myocardial infarction patients in the Rotterdam area of the Netherlands: outstanding short-term and long-term results].

    by E Boersma, A C Maas, J A Hartman, B Ilmer, J Vos, M L Simoons

    To describe the results of thrombolysis prior to hospitalisation in patients with evolving myocardial infarction. Prospective cohort study. The 'Reperfusion for acute infarcts Rotterdam' (Dutch acronym: REPAIR) programme aims to minimise treatment delay in patients with evolving myocardial infarction by the initiation of thrombolytic therapy prior to hospital admission. For patients with symptoms that indicate a developing myocardial infarction, treatment is initiated immediately by the ambulance personnel at the patient's home, once the diagnosis has been confirmed with the help of a portable 12-lead ECG system. The interval between the onset of symptoms and the thrombolysis infusion was recorded for all patients, as well as any complications which occurred during transportation. The long-term survival was determined using data from the municipal registration. In the period 1988-2000, 1487 patients were treated using the REPAIR protocol, 80% of these within two hours after the onset of symptoms. In 9 cases (0.6%) a thrombolytic treatment had been initiated, whereas the diagnosis 'myocardial infarction' was not confirmed at the hospital. During transport 40 patients (2.7%) experienced ventricle fibrillation, 25 (1.7%) severe hypotension, and 2 patients (0.1%) died. Mortality at 30 days and at one, five, and ten years was 4.9%, 7.3%, 16.2% en 30.1%, respectively. Patients treated within two hours after the onset of symptoms had lower mortality rates than those treated later: at one year 6.7% versus 9.7%, and at 5 years 14.0% versus 25.1% (Kaplan-Meier estimates; log rank test: p = 0.001). Immediate thrombolytic treatment of patients with a developing myocardial infarction which could be safely initiated by ambulance personnel, resulted in excellent short-term and long-term survival.


    • 16 December 2000
      • Vol. 144  (51) , 2442-4

    [Cholesterol-lowering therapy; a recommendation from the Health Council].

    by M L Simoons

    The recent report on lipid lowering therapy from the Netherlands Health Council is largely in agreement with the 1998 guidelines made at the Dutch Institute for Health Care Improvement CBO on the same topic. In addition to advice for a healthy life style and no smoking, lipid lowering therapy (particularly statins) is recommended in: patients with familial hyperlipidaemia; patients with atherosclerotic disease and a total cholesterol > 5.0 mmol/l; patients with diabetes and multiple risk factors including a total cholesterol > 5.0 mmol/l; other persons with markedly increased risk for development of coronary artery disease. The report does not dwell upon implementation and effects of the recommendations or on the question what preventive efforts are desirable for persons without manifest cardiovascular disease. In practice, prescribing the recommended medication is more successful than attempts to change the life style. The effects of multifactorial life style intervention may be considerable, however. The high social costs of cholesterol-lowering treatment should be regarded as an investment in health.


  • The challenge of acute coronary syndromes

    by Maarten L Simoons, Eric Boersma, Coen van der Zwaan, Jaap W Deckers


    • 1 September 1998
      • p. J56-60

    EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease.

    by M L Simoons, J Vos, P J De Feyter, M L Bots, W J Remme, D E Grobbee, C Kluft, M P De Maat, K M Fox, J W Deckers

    In patients with coronary disease, ACE inhibitors may improve endothelial function in the coronary arteries as well as peripheral arteries, and may have anti-proliferative effects which might result in retardation of progression of coronary artery disease. In order to verify these pathophysiological concepts, a series of substudies will be conducted as part of the EUROPA programme. Angiographic and intravascular ultrasound examination of coronary arteries will be performed in approximately 400 patients before and after 3 years' treatment with either perindopril or placebo, in order to assess progression and possible regression of coronary lesions. B-mode ultrasonography of the brachial artery will be used as a model for changes in the coronary arteries, to assess endothelial function in response to ischaemia (reactive hyperaemia) and to vasoconstriction (cold pressor test). Three hundred patients will be investigated before and at different intervals after initiation of study treatment. In addition genetic characterization will be performed of patients participating in EUROPA in order to assess whether specific genotypes do respond more or less favourably to perindopril. In addition, the effect of perindopril will be investigated in patients with diabetes type II, since ACE inhibition in such patients may improve microvascular function and renal function. Integration of these substudies, as well as detailed analysis of other specific subgroups in EUROPA, will help us understand the effects of treatment with perindopril in patients with stable coronary artery disease.